Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cell–Depleting Therapies in Autoimmune Diseases in the Genomic Era


  • Michael L. Whitfield

    Corresponding author
    1. The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
    Search for more papers by this author
    • Dr. Whitfield also is a scientific founder of Celdara Medical LLC.

      Dr. Whitfield has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers Squibb, Shire, and Johnson & Johnson (less than $10,000 each). He receives royalties for patents regarding scleroderma biomarkers and has submitted patent applications for gene expression biomarkers in scleroderma.